NC Medical Research

NC Medical Research is a Japanese biotechnology company focused on the research and development of cell therapy drugs. Founded in December 2004, the company's primary mission is to establish treatments for nerve damage caused by conditions like stroke by leveraging the body's natural healing capabilities. The company name, NC, stands for "Neural Cell."

The firm's main development pipeline is NCS-01, a therapeutic product for acute ischemic stroke derived from bone marrow mesenchymal stem cells. This product is developed using a proprietary two-stage screening process to select cell populations with neuroprotective effects. NC Medical Research operates on a fabless model, collaborating with research development consultants and contract manufacturing organizations (CMOs) to advance its research. The company has engaged in partnerships and received funding from entities like Fujifilm and others.

NC Medical Research was established as a subsidiary of e-solutions, Inc. The development of its stroke treatment, NCS-01, began in the United States in 2007, with non-clinical trials starting in 2009. The company received approval for its Investigational New Drug (IND) application from the U.S. FDA in July 2019, and clinical trials commenced in the U.S. in February 2020. As of 2024, the company is also preparing for clinical trials in Japan. The company's board includes Chairman Keishin Sasaki, who is also the President & CEO of e-solutions, Inc., and President and CEO Hiroyuki Mitani, who assumed the role in July 2021.

Keywords: regenerative medicine, cell therapy, acute stroke treatment, biotechnology, NCS-01, neural cell, neuroprotective, mesenchymal stem cells, clinical trials, drug development, pharmaceutical research, stroke therapy, bone marrow-derived cells, fabless biotech, IND approval, e-solutions Inc.